Background
Materials and methods
Cell lines and breast tumor specimens
siRNA, miRNA, plasmid construction, transfection, and luciferase assays
Immunoblotting
RNA extraction and quantification of miRNAs
Establishment of gemcitabine resistant cell line
TUNEL assays
Proliferation assays
miRNA targets prediction
Statistical analysis
Results
miR-200a plays a role in chemoresistance of breast cancer cells
miR-200a expression promotes chemoresistance in breast cancer cell lines
Overexpression of miR-200a induced chemoresistance was mediated through TP53INP1 and YAP1
Overexpression of miR-200a was associated with poor response to preoperative chemotherapy and poor prognosis in patients with breast cancer
Clinicopathologic parameters | Number of cases | Median expression of miR-200a (normalized CT)a |
P
|
---|---|---|---|
Age,y | 0.731 | ||
≤ 40 | 13 | 10.60 ± 2.870 | |
> 40 | 59 | 10.36 ± 2.939 | |
Histological type | 0.892 | ||
DCIS | 3 | 10.63 ± 1.572 | |
IDC | 69 | 10.39 ± 2.959 | |
Menstrual status | 0.272 | ||
Menstrual | 38 | 10.05 ± 2.514 | |
Menopause | 34 | 10.81 ± 3.285 | |
TNM stage | 0.918 | ||
II | 28 | 10.45 ± 3.601 | |
III | 44 | 10.38 ± 2.412 | |
Tumor size | 0.839 | ||
T1 + T2 | 32 | 10.48 ± 2.639 | |
T3 + T4 | 40 | 10.34 ± 3.138 | |
Chemotherapy response | 0.0021 | ||
PD + SD | 22 | 8.958 ± 2.586 | |
PR | 50 | 11.04 ± 2.835 | |
ER | 0.277 | ||
Negative | 27 | 9.920 ± 2.648 | |
Positive | 45 | 10.69 ± 3.045 | |
PR | 0.501 | ||
Negative | 23 | 10.06 ± 2.166 | |
Positive | 49 | 10.56 ± 3.206 | |
Her2 | 0.515 | ||
Negative | 52 | 10.54 ± 3.049 | |
Positive | 20 | 10.04 ± 2.541 | |
All cases | 72 | 10.40 ± 2.908 |